Myeloid leukemias are among the most aggressive blood cancers and have low survival rates. Today, leukemia patients undergo genetic analysis to identify mutations and select the most appropriate treatment. However, even among patients with the same mutation, disease progression and response to therapy can vary significantly.
Leave A Comment